TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06192979

Intervention type: DRUG
Group type: OTHER
Intervention: Daratumumab
Description: Daratumumab 16 mg/kg was administered intravenously weekly in cycles one and two, every two weeks for cycles three to six, for at least 6 cycles.~Daratumumab and hyaluronidase-fihj 1800mg is allowed according to the patients' choice.

Intervention type: DRUG
Group type: OTHER
Intervention: Daratumumab
Description: Daratumumab 16 mg/kg was administered intravenously weekly in cycles one and two, every two weeks for cycles three to six, for at least 6 cycles.~Daratumumab and hyaluronidase-fihj 1800mg is allowed according to the patients' choice.

Intervention type: DRUG
Group type: OTHER
Intervention: Bortezomib
Description: All patients received 1.0-1.3 mg/m2 subcutaneous bortezomib once weekly of 28 days each for at 6 cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: All patients received 20-40 mg oral or intravenous dexamethasone

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: All patients received 20-40 mg oral or intravenous dexamethasone

Intervention type: DRUG
Group type: OTHER
Intervention: Venetoclax
Description: All patients received venetoclax 400mg daily.
Study: NCT05373550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effectiveness of a nursing educational intervention on quality of life, sexual function, and self-esteem in hysterectomized women: a mixed method approach.
Description: Effectiveness of a nursing educational intervention supported by a technological tool (Libre mujer), on quality of life, sexual function and self-esteem in hysterectomized women: a mixed method approach.
Study: NCT05680558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis
Description: Extracorporeal Photopheresis (ECP)
Study: NCT04905017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Tricuspid Valve Replacement
Description: Replacement of the tricusupid valve using Trisol System in a transcatheter approach
Study: NCT05680558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERAKOS® CELLEX photopheresis system
Description: THERAKOS® CELLEX is an FDA-approved extra-corporeal photopheresis system
Study: NCT06141317

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PASC transplantation (25 million PASCs/patient)
Description: 3 doses of 25 million PASCs implantation via peripheral vein (Day 0, 3 months, 6 months)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 0.9% saline solution via peripheral vein (Day 0, 3 months, 6 months)
Study: NCT05430620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Active oxygenation during hypothermic machine perfusion by bubble and surface oxygenation. Intermittent surface oxygenation is compared with continuous surface oxygenation during hypothermic machine perfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Active oxygenation during hypothermic machine perfusion by bubble and surface oxygenation. Intermittent surface oxygenation is compared with continuous surface oxygenation during hypothermic machine perfusion
Study: NCT05679414

Intervention type: DIAGNOSTIC_TEST
Intervention: RT- PCR of 2 ml EDTA blood sample to determine MTHFR C677T genotypes
Description: Venous blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: RT- PCR of 2 ml EDTA blood sample to determine MTHFR C677T genotypes
Description: Venous blood sample
Study: NCT06501859

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care physical therapy
Description: Standard rehabilitation protocol for 3 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shoulder pacemaker with physical therapy
Description: Standardized rehabilitation protocol with utilization of the shoulder pacemaker device 3 times per week over a 3-month period.
Study: NCT05477186

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0501 (3 μg)
Description: Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0501 (6 μg)
Description: Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0501 (12 μg)
Description: Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0501 (25 μg)
Description: Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0501 (50 μg)
Description: Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0501 (75 μg)
Description: Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0501 (100 μg)
Description: Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0501 (100 μg)
Description: Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0501 (150 μg)
Description: Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0501 (200 μg)
Description: Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
Study: NCT06273995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: All participants will undergo behavioral activation treatment for 8-10 weeks
Study: NCT05926427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: 150 mg qd po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during 2 years of follow-up

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 ivgtt, D0 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Not specified, recommended regimen according to histopathologic type
Study: NCT06020794

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: quadriceps isometric exercises, straight leg raises, semi-squat exercises, hip flexors, hamstring and iliotibial band stretching exercises, strengthening exercises for hip abductors and adductors

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: quadriceps isometric exercises, straight leg raises, semi-squat exercises, hip flexors, hamstring and iliotibial band stretching exercises, strengthening exercises for hip abductors and adductors
Study: NCT05319873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given SC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary Studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary Studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary Studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Given IV
Study: NCT06020794

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LP-PRP
Description: The LP-PRPs to be applied will be obtained by centrifugation of the venous blood taken from the patients by manual methods.
Study: NCT05319873

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Given PO
Study: NCT06343857

Intervention type: DIAGNOSTIC_TEST
Intervention: self-assessment questionnaire
Description: Completion of the anatomical site-specific self-assessment questionnaire.
Study: NCT06506591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-890
Description: Administered P.O.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-890
Description: Administered P.O.
Study: NCT04761796

Intervention type: OTHER
Intervention: Sleeping condition self-questionnaire
Description: Professional flight members will answer a self questionnaire related to their sleeping conditions
Study: NCT06119880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancreatin Enteric-coated Capsules
Description: pancreatic enzyme replacement therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine treatment plan
Description: Routine treatment plan without PERT
Study: NCT06077084

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: 4months with multimodal physiotherapy. 2 sessions/week. Sessions consisted of two sessions of 1 hour per week, focusing on neck and arm movements. Each session included education and manual therapy (20 minutes), and exercises targeting neck extensors, flexors, and shoulder girdle muscles (40 minutes).~Low-intensity neck resistance training :~Participants have to perform arm, neck flexors and extensors exercise. motor control exercises focusing on deep neck muscles, slow dynamic and static contractions (10 to 20 seconds) with low resistance using TheraBand and weights ranging from 0.5 kg to 1 kg.~High-Intensity Neck resistance training :~neck flexors exercise, neck extensors exercise, and one exercise for shoulder/upper limb. static contractions (10-seconds) and dynamic neck movements using a handheld biofeedback dynamometer or weights from 50% to 80% of the 1-repetition maximum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: 4months with multimodal physiotherapy. 2 sessions/week. Sessions consisted of two sessions of 1 hour per week, focusing on neck and arm movements. Each session included education and manual therapy (20 minutes), and exercises targeting neck extensors, flexors, and shoulder girdle muscles (40 minutes).~Low-intensity neck resistance training :~Participants have to perform arm, neck flexors and extensors exercise. motor control exercises focusing on deep neck muscles, slow dynamic and static contractions (10 to 20 seconds) with low resistance using TheraBand and weights ranging from 0.5 kg to 1 kg.~High-Intensity Neck resistance training :~neck flexors exercise, neck extensors exercise, and one exercise for shoulder/upper limb. static contractions (10-seconds) and dynamic neck movements using a handheld biofeedback dynamometer or weights from 50% to 80% of the 1-repetition maximum
Study: NCT04972994

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic intracorporeal versus extracorporeal anastomosis for right and left hemicolectomies
Description: laparoscopic intracorporeal versus extracorporeal anastomosis for right and left hemicolectomies in management of colonic cancers

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic intracorporeal versus extracorporeal anastomosis for right and left hemicolectomies
Description: laparoscopic intracorporeal versus extracorporeal anastomosis for right and left hemicolectomies in management of colonic cancers
Study: NCT05740241

Intervention type: OTHER
Intervention: Elderly
Description: A group of participants with physical activity (protocolized)
Study: NCT04741373

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral nutritional supplements
Description: oral nutritional supplements, 400-600kcal/day;

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation exercise
Description: Aerobic exercise: fixed cycling in rehabilitation center or walking at home, 3-5 times/week, Resistance exercise: lift dumbbell by upper limb, raise legs tying sandbags, 2-3 times/week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rehabilitation exercise
Description: Aerobic exercise: fixed cycling in rehabilitation center or walking at home, 3-5 times/week, Resistance exercise: lift dumbbell by upper limb, raise legs tying sandbags, 2-3 times/week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: health education
Description: Establish WeChat group or QQ group or telephone contact, and regularly distribute electronic science pictures or small videos

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: health education
Description: Establish WeChat group or QQ group or telephone contact, and regularly distribute electronic science pictures or small videos

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health education
Description: Establish WeChat group or QQ group or telephone contact, and regularly distribute electronic science pictures or small videos
Study: NCT06544278

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic product
Description: During the experiment, subjects take one sachet probiotic product daily. Evaluation is conducted by monitoring the subjects' semen concentration before and after this trial.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: During the experiment, subjects take one sachet maltodextrin daily with 3.0g. Evaluation is conducted by monitoring the subjects' semen concentration before and after this trial.
Study: NCT05939297

Intervention type: OTHER
Intervention: Heart Health Self-efficacy and Self-Management Scale
Description: In order to measure the self-management and self-efficacy levels of the individuals, patients will be administered the Heart Health Self-efficacy and Self-Management Scale.

Intervention type: OTHER
Intervention: Self-Care Management Scale in chronic diseases
Description: For the external construct validity statistical method, the self-management level of the individuals will also be determined with the Self-Care Management in Chronic Diseases Scale, which has been previously validated and reliable in Turkish.

Intervention type: OTHER
Intervention: general self-efficacy scale
Description: For the external construct validity statistical method, the self-efficacy level of the individuals will also be determined with the general self-efficacy scale, which has been previously validated and reliable in Turkish.
Study: NCT06506591

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WD-890 Tablets Placebo
Description: Administered P.O.
Study: NCT06297252

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: standardized clinical psychiatric evaluations
Description: The intervention consists of a psychiatric consultation including :~* assessment of psychiatric disorders using a MINI test~* information gathering (medical, obstetrical and family history, expected term of pregnancy).~* assessment of suicidal behaviour using the Columbia-Suicide Severity Rating Scale (CSSR-S)~* collection of negative life events over the past 12 months, assessed using the Paykel questionnaire

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: self-administered psychiatric questionnaire assessments
Description: * EPICES Score: (Evaluation de la Précarité et des Inégalités de santé dans les Centres d'Examens de Santé):~* MIBS: (Mother to Infant Bonding Scale)~* PAI: (Prenatal Attachment Inventory)~* EDEQ: (Eating Disorder Examination Questionnaire)~* PCL-5: (Post-traumatic Stress Disorder Checklist for DSM-V)~* MARS: (Medication Adherence Rating Scale)~* EPDS: (Edinburgh Postnatal Depression Scale)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: A blood sample is taken to form an optional biological collection, comprising 3 samples:~* A tube to collect RNA from whole blood.~* A tube to collect serum~* A tube to collect native DNA
Study: NCT05258370

Intervention type: OTHER
Intervention: Dosage
Description: Evaluation of circulating C-terminal FGF23 (FGF23Ct) rate, circulating intact FGF23 (FGF23i) rate and Erythropoietin

Intervention type: OTHER
Intervention: Cardiac echography
Description: 12 months after patient enrollment
Study: NCT05877131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: To evaluate the efficacy of low-dose levobupivacaine (0.125%) (0.2) in avoiding hemodynamic changes after performing regional analgesia in pregnant women in labor and preventing changes in fetal heart rate and cardiotocographic recording.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: To evaluate the efficacy of low-dose ropivacaine (0.2) in avoiding hemodynamic changes after performing regional analgesia in pregnant women in labor and preventing changes in fetal heart rate and cardiotocographic recording.
Study: NCT05612919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red blood cell from umbilical cord blood
Description: Patients will receive a volume of 15-20 ml/kg of red blood cell from umbilical cord blood (UCB-RBC). The transfusion will be prescribed and administered with all the routine safety measures carried out by the nurses to ensure compatibility between the administered RBC and the patient. The UCB-RBC bags will contain a minimum volume of 20 mL of RBC, with a haematocrit of about 60% and an acceptable residual leucocyte content of \<106/mm3.~Product validation is currently under development.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell from adult donor
Description: Patients will receive a volume of 15-20 ml/kg of red blood cell from adult donor according to standard guidelines.~The transfusion will be prescribed and administered with all the routine safety measures carried out by the nurses to ensure compatibility between the administered RBC and the patient.~Blood samples are irradiated according to standard practise.
Study: NCT04897867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolSculpting® Elite System with CoolSculpting® Elite applicators
Description: A treatment session is comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage.
Study: NCT05329116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Injectable Solution
Description: Patients will be administered 1.5 ml of 2% lidocaine, 1.5 ml of 30 mg of pentoxifylline.~Among the injection techniques, profundal intradermic injection (IDP, injection depth: 2-4 mm) and superficial intradermic injection (IDS, injection depth: 1-2 mm) will be used.~8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich plasma
Description: 8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich plasma
Description: 8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection
Study: NCT04990921

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Palliative Radiation and Pembrolizumab
Description: Stereotactic radiation therapy will be administered as clinically indicated.
Study: NCT04600167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid and Rifapentine (INH-RPT)
Description: Oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the control group will receive placebo once weekly for 12 weeks
Study: NCT05804799

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast-enhanced liver CT scan
Description: The contrast-enhanced liver CT scans were obtained from all of the participants.~The liver CT images were reconstructed by both low-dose scans with a deep-learning-based denoising program (ClariCT.AI) and standard-dose scans with model-based iterative reconstruction.
Study: NCT06151392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Formula
Description: probiotic will be administered to pediatric patients with ventriculitis to study their possible effect in treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Formula
Description: probiotic will be administered to pediatric patients with ventriculitis to study their possible effect in treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: Zinc will be administered to pediatric patients with ventriculitis to study their possible effect in treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: Zinc will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
Study: NCT05123235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: the participants will be encouraged to set their own physical activity goals weekly and using behavioral strategies work towards meeting those goals. The behavioral strategies will be discussed weekly for 30 minutes a telehealth method.